Neuphoria Therapeutics Files 8-K

TL;DR

Neuphoria Therapeutics filed an 8-K on Oct 20, 2025. Details TBD.

AI Summary

Neuphoria Therapeutics Inc. filed an 8-K on October 20, 2025, reporting other events and financial statements. The company, formerly known as Bionomics Limited/FI, is incorporated in Delaware and headquartered in Burlington, Massachusetts. This filing does not appear to contain specific financial figures or details about the 'other events' beyond its classification.

Why It Matters

This 8-K filing indicates Neuphoria Therapeutics Inc. is making a regulatory disclosure, which could contain important updates for investors regarding company events or financial status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K notification without immediate disclosed material financial impact or significant operational changes.

Key Players & Entities

• Neuphoria Therapeutics Inc. (company) — Registrant
• BIONOMICS LIMITED/FI (company) — Former Company Name
• October 20, 2025 (date) — Date of Report
• 001-41157 (other) — Commission File Number
• 99-3845449 (other) — I.R.S. Employer Identification No.
• 100 Summit Dr, Burlington, Massachusetts 01803 (address) — Principal Executive Offices
• 781-439-5551 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.00001 — nge on which registered Common Stock, $0.00001 par value per share NEUP The Nasdaq
• $450 million — Neuphoria is eligible to receive up to $450 million in additional milestone payments for ce
• $14.2 million — phoria's cash and cash equivalents were $14.2 million. The Company expects its current cash p

Filing Documents

• ea0261841-8k_neuphoria.htm (8-K) — 40KB
• ea026184101ex99-1_neuphoria.htm (EX-99.1) — 15KB
• ex99-1_001.jpg (GRAPHIC) — 2KB
• 0001213900-25-100371.txt ( ) — 228KB
• neup-20251020.xsd (EX-101.SCH) — 3KB
• neup-20251020_lab.xml (EX-101.LAB) — 33KB
• neup-20251020_pre.xml (EX-101.PRE) — 22KB
• ea0261841-8k_neuphoria_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On October 20, 2025, Neuphoria Therapeutics Inc. (the "Company") announced topline results from its AFFIRM-1 Phase 3 trial of BNC210 for the acute treatment of social anxiety disorder (SAD) that it did not meet its primary endpoint of change from baseline to the average of the performance phase of the public speaking challenge in Subjective Units of Distress Scale (SUDS) scores. In addition, analyses of secondary endpoints did not demonstrate statistically significant differences or improvement over placebo. Business Update and Outlook Based on the results from the AFFIRM-1 trial: Neuphoria will discontinue further development of its SAD program. Based upon previous positive data with chronic daily dosing, Neuphoria plans to continue to evaluate next steps, if any, for further development of BNC210 in post-traumatic stress disorder (PTSD). The Company plans to conduct a full strategic review of its operations, portfolio and to provide an update by or before year-end. Additionally, as previously and more fully disclosed and described in our SEC reports, the Company has an ongoing partnership with Merck & Co., Inc. (Merck). MK-1167, one of two positive allosteric modulator (PAM) candidates being advanced in the strategic partnership with Merck, is currently being evaluated in a Merck-led Phase 2 trial in Alzheimer's disease. Merck is responsible for all costs of this program, and through the partnership, Neuphoria is eligible to receive up to $450 million in additional milestone payments for certain development and commercial milestones plus royalties on net sales of any licensed medicines. Safety and Tolerability The safety and tolerability profile of BNC210 continued to be favorable and was consistent with previously reported studies. Cash Position at June 30, 2025 As of June 30, 2025, our most recent publicly reported period, Neuphoria's cash and cash equivalents were $14.2 million. The Company expects its current cash posi

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements that involve risks and uncertainties. Statements included herein that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking Company to maintain the listing of its securities on Nasdaq and the risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission. The forward-looking statements are based on our current beliefs, plans, burn rate and expectations. Certain forward-looking statements, including (without limitation) about (1) Neuphoria's ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement and/or completion of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Neuphoria's financial resources, and (4) assumptions underlying any such statements. The inclusion of forward-looking statements should not be regarded as a representation by Neuphoria that any of its plans will be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. Certai

01 Financial Statements

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release, dated October 20, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3

SIGNATUREs

SIGNATUREs Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NEUPHORIA THERAPEUTICS INC. By: /s/ Spyridon Papapetropoulos Spyridon Papapetropoulos Chief Executive Officer Date: October 20, 2025 4

View Full Filing

View this 8-K filing on SEC EDGAR